Company intelligence / Profile preview
Tranzyme Pharma
Durham, North Carolina, USAtranzyme.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tranzyme Pharma developed novel small molecule macrocyclic drugs using its proprietary MATCH™ technology. The company advanced several internal programs targeting GI motility disorders into clinical trials and established major pharma collaborations. In early 2013, it merged with Ocera Therapeutics to form a NASDAQ-listed company focused on liver disease therapeutics.
- Therapeutic areas
- GastroenterologyMetabolic Disorders
- Modalities
- Small molecules (specifically macrocyclic compounds)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Bristol Myers Squibb (major drug discovery collaboration using MATCH™ technology)Shin Nippon Biomedical Laboratories (SNBL) for non-human primate modelsvarious pharma partners through outlicensing/discovery deals
Beyond the preview
Go deeper on Tranzyme Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tranzyme Pharma.